Looking back over the past 12 months, the All Ordinaries (INDEXASX: XAO) has performed strongly, rising just over 15%. However, there are a number of shares that stood out and have managed to do even better.
Below are three shares that have not only beaten the market, but would have more than doubled your investment from one year ago today.
Catapult Group International Ltd (ASX: CAT)
12 months ago, the Catapult share price closed at just $0.605. Fast forward to today and investors are now willing to pay $2.00 for them, a massive 230% increase. So, what’s happened?
Catapult was founded in 2006 and is a leader in the emerging field of sports analytics. The company’s wearable devices collect data through sensors which feed through to its proprietary software and analytics programs. This software is then capable of producing a range of simple and complex metrics.
On this very day in February last year, Catapult shocked the market by announcing the resignation of its CEO, Joe Powell. This was announced only a couple months after the resignation of the company’s then CFO, Mark Hall.
These events caused the Catapult share price to drop to its 52-week low of $0.60, meaning shares were trading on an enterprise value multiple of just 1.5x sales.
Now, given that Catapult was running a high margin, sticky software business and growing revenue at 20% per year, hindsight may have screamed value. And it didn’t take long for its share price to track back up thanks to revenue growth, the appointment of Will Lopes as CEO, and a series of new contract wins. On this, Catapult recently announced a new league-wide deal with Major Rugby League (MLR).
Catapult seems to have found traction recently making a number of large deals, indicating there may be plenty of steam left in it still.
Nanosonics Ltd. (ASX: NAN)
Nanosonics sells a medical device called trophon. Trophon is used to sterilise ultrasound probes with the advantages of being automated and quicker while not requiring any chemicals.
Thanks to its trophon product, and the release of trophon2, Nanosonics grew sales by 39% in FY19. The company also looks set to expand into new markets, announcing agreements in Europe and regulatory approval in Japan.
Despite Nanosonics’ fast growth, it’s estimated that the company has only achieved a global market penetration of 17%. This gives it plenty of room to move higher in the future thanks to the superiority of its products. What’s more, Nanosonics’ product suite is also expanding due to investment in research and development.
Over the past 12 months, Nanosonics shares have risen a tremendous 114% to sit at $7.34 today.
Medical Developments International Ltd (ASX: MVP)
Medical Developments shares traded for just $3.71 a year ago. Today, a share in this fast-growing company will cost you $10.63, a tidy 187% increase.
This share price growth was driven by the company’s growth in revenue, as well as its expanding global footprint and outlook. In FY19, revenues reached a record high and net profit after tax was up a staggering 327%, albeit off a low base.
Meanwhile, sales of the company’s flagship Penthrox medicine increased 47% globally. This was largely driven by almost 400 new customers in Europe and 1058 customers in total.
It appears the market has been impressed with Medical Development’s past growth and is excited about its future. Medical Developments is in the approvals process to sell Penthrox in the lucrative United States, Chinese and Russian markets which would no doubt go a long way to helping it continue its amazing run.
The post These 3 ASX shares would have doubled your money in 12 months appeared first on Motley Fool Australia.
Missed on out these standout performers? Be sure to check out the five ASX growth shares in the free report below.
Our experts here at The Motley Fool Australia have just released a fantastic report, detailing 5 dirt cheap shares that you can buy in 2020.
One stock is an Australian internet darling with a rock solid reputation and an exciting new business line that promises years (or even decades) of growth… while trading at an ultra-low price…
Another is a diversified conglomerate trading near a 52-week low all while offering a 2.7% fully franked yield...
Plus 3 more cheap bets that could position you to profit over the next 12 months!
See for yourself now. Simply click the link below to scoop up your FREE copy and discover all 5 shares. But you will want to hurry – this free report is available for a brief time only.
- Man bets $221,666 on one ASX stock
- Top analysts name their top 3 ASX blue chip shares for 2019
- 3 quality dividend shares to boost your income
- NEW: Free report names top 3 ASX dividend shares to buy for 2019
- 5 Stocks for Potentially Building Wealth After 50
Michael Tonon owns shares of Catapult Group International Ltd. The Motley Fool Australia's parent company Motley Fool Holdings Inc. owns shares of Catapult Group International Ltd, Medical Developments International Limited, and Nanosonics Limited. The Motley Fool Australia has recommended Catapult Group International Ltd, Medical Developments International Limited, and Nanosonics Limited. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.
The Motley Fool's purpose is to help the world invest, better. Click here now for your free subscription to Take Stock, The Motley Fool's free investing newsletter. Packed with stock ideas and investing advice, it is essential reading for anyone looking to build and grow their wealth in the years ahead. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson. 2020